ADHD Diagnoses Rise in Europe Due to Awareness, Professor Anita Thapar Says

Europe-wide attention deficit hyperactivity disorder diagnoses are increasing significantly due to rising awareness and changing diagnostic standards rather than a true epidemiological increase in the condition, according to findings presented by Professor Anita Thapar at the 39th ECNP Congress in Munich.

Key Clinical Takeaways:
• Diagnosed prevalence for ADHD across Europe has climbed significantly over recent years, driven largely by improved clinical recognition and evolving diagnostic criteria.
• Population-level prevalence remains stable at roughly 5% to 7% of children and 2% to 3% of adults, indicating that many countries still experience under-diagnosis.
• Prescription rates have surged threefold in the UK between 2010 and 2023, with adult women driving particularly sharp increases in treatment use.

Assessing the European Diagnostic Surge in Munich

Referrals and treatment rates for attention deficit hyperactivity disorder are climbing across the United Kingdom and continental Europe, a trend taking center stage at the 39th ECNP Congress in Munich. Presenting a synthesis of evidence, Professor Anita Thapar of Cardiff University stated that the rise stems primarily from shifts in diagnostic criteria, better public and professional awareness, and accumulated research on risks, rather than an epidemic of the condition. Professor Thapar chaired the NHS England ADHD taskforce and co-chaired the Welsh Government Neurodivergence Ministerial Advisory Group.

Comparing Population Rates With Clinical Diagnoses

A crucial distinction exists between diagnosed prevalence—the total number of clinically recognized cases recorded within health systems—and population prevalence, which describes the expected community rate determined through epidemiological research. The underlying population rate of ADHD remains approximately 5% to 7% of children and 2% to 3% of adults across Europe, figures that have stayed broadly consistent. In certain nations, recognized diagnoses now match this population rate, while in the United Kingdom, diagnosed rates sit well below expected figures. Professor Thapar compared this trajectory to historical patterns observed with hypertension and high lipid levels in the 1960s, where routine identification grew as medical recognition caught up with reality.

Tracking Prescription Trends Across European Health Systems

Medication use has expanded alongside diagnostic recognition. Published data cited in the research confirm increased ADHD medication use in Belgium, Germany, the Netherlands, Spain, and the UK between 2010 and 2023. In the UK specifically, the prevalence of medication use rose more than threefold over this timeframe, shifting from 0.12% to 0.39%. Adult use increased particularly sharply among women, reflecting a historical gap where female presentation was frequently neglected.

Addressing Diagnostic Thresholds and Clinical Interventions

Having ADHD does not operate as a simple binary outcome. Much like blood pressure or cholesterol, symptom severity exists along a continuous spectrum, and the point where doctors intervene depends on moving diagnostic thresholds. Current evidence shows that treatment can mitigate known risks associated with unmanaged ADHD, including premature mortality and suicide.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.